Trials / Completed
CompletedNCT01567683
A Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of a New Topical Formulation Containing 0,09% Imiquimod (Limtop) in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Moberg Pharma AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This study is designed to assess the tolerability of test product and vehicle in terms of skin reactions during repeated topical applications on healthy skin under controlled conditions on the basis of the international guidelines for testing of skin irritations (FDA Guidance for Industry (1999)).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imiquimod (topical use) |
Timeline
- First posted
- 2012-03-30
- Last updated
- 2012-05-28
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT01567683. Inclusion in this directory is not an endorsement.